January 16, 2024 02:31 PM EST
R&D
Pharma

Mer­ck adds third cer­vi­cal can­cer nod for Keytru­da, bring­ing to­tal ap­provals to 39

Katherine Lewin

News Reporter

Mer­ck’s Keytru­da scored its third US ap­proval in cer­vi­cal can­cer, mak­ing it the first and on­ly an­ti-PD-1 ther­a­py ap­proved as a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Cell ther­a­py start­up A2 Bio­ther­a­peu­tics nets $80M Se­ries C

A service from the Financial Times